Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.61 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.61 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8792890 | 0.89 | MRGPRX4 (0.52) | FOLH1ANPEPENPEPMRGPRX4 | |
| SCHEMBL9622159 | 0.87 | ANPEP (0.69) | FOLH1ANPEPENPEP | |
| SCHEMBL14478232 | 0.87 | ANPEP (0.69) | FOLH1ANPEPENPEP | |
| SCHEMBL8375490 | 0.87 | FOLH1 (0.59) | FOLH1ANPEPENPEPMEP1BMRGPRX4 | |
| SCHEMBL1397444 | 0.87 | ANPEP (0.69) | FOLH1ANPEPENPEP | |
| SCHEMBL9209594 | 0.86 | FOLH1 (0.62) | FOLH1ANPEPENPEPMEP1BMRGPRX4 | |
| Hydrochloric Acid SCHEMBL27656347 | 0.86 | ANPEP (0.67) | FOLH1ANPEPENPEP | |
| SCHEMBL27751364 | 0.86 | FOLH1 (0.58) | FOLH1ANPEPENPEPMEP1BMRGPRX4 | |
| SCHEMBL6072390 | 0.86 | ATM (0.57) | FOLH1 | |
| SCHEMBL27752467 | 0.86 | FOLH1 (0.58) | FOLH1ANPEPENPEPMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| CN-113321640-B | Indole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-06-09 | — | — | CN | disclosed |
| CN-109111427-B | Indole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-06-02 | — | — | CN | disclosed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| WO-2021110120-A1 | ANTI-TUMOR VACCINE MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 华中师范大学 | 2021-06-10 | — | — | WO | disclosed |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2020-11-05 | — | — | US | disclosed |
| US-10335425-B2 | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-1763509-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006002474-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-12 | — | — | WO | disclosed |
| US-6984637-B2 | Cyclic amine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| US-6683074-B1 | PYRROLIDINYL, PIPERAZINYL AND AZEPINYL DERIVATIVES; INFLAMMATORY OR ALLERGIC DISEASES | SYNTEX (U.S.A.) LLC | 2004-01-27 | — | — | US | disclosed |
| US-6339087-B1 | FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS | SYNTEX (U.S.A.) LLC | 2002-01-15 | — | — | US | disclosed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | FOLH1 4333/4885ANPEP 1545/4885ENPEP 1202/4885 |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | FOLH1 3172/4885ANPEP 3093/4885ENPEP 2674/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | FOLH1 4333/4885ANPEP 1545/4885ENPEP 1202/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | FOLH1 4333/4885ANPEP 1545/4885ENPEP 1202/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | FOLH1 745/4885ANPEP 1189/4885ENPEP 1358/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | FOLH1 745/4885ANPEP 1189/4885ENPEP 1358/4885 |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | FOLH1 3172/4885ANPEP 3093/4885ENPEP 2674/4885 |
| US-10335425-B2 | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors | BTD, TREH, SI | FOLH1 466/4885ANPEP 190/4885ENPEP 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.